EARLY SUCCESSES JUST THE TIP OF THE ICEBERG FOR 3D BIOPRINTING
As Rainbow Coral Corp. (RBCC) and its joint venture partners continue to market and develop breakthrough biotechnology innovations. The healthcare applications for 3D printing technology are increasing every day. Researchers all across the globe are printing everything from knee joints to heart valves to kidney tissue and changing lives with custom creations.
But even these startling achievements are only the tip of the iceberg of the 3D bioprinting advancements to come, says RBCC CEO Kimberly Palmer.
“3D bioprinting is the first practical step toward true, regenerative medicine,” says Palmer, “It is the future of healthcare.”
RBCC FORMS JOINT VENTURE WITH CUTTING-EDGE DRUG DELIVERY COMPANY THERAKINE
As part of a bold expansion into the $60 billion global drug delivery market, Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (RBCC), announced it has formed a new partnership to solve the problems posed by systemic drug delivery.
RBCC signed a joint venture agreement with TheraKine Ltd, the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. The company has developed and patented these innovative, complimentary technologies to potentially enable selective, site-specific drug delivery, allow for lower drug concentrations and significantly reducing the risk of drug toxicity.
“It is the future of healthcare.”